| Basics |
Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.
|
| IPO Date: |
March 16, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$7.45B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.38 | 2.14%
|
| Avg Daily Range (30 D): |
$0.92 | 1.34%
|
| Avg Daily Range (90 D): |
$0.89 | 1.27%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.97M |
| Avg Daily Volume (30 D): |
1.97M |
| Avg Daily Volume (90 D): |
1.8M |
| Trade Size |
| Avg Trade Size (Sh.): |
105 |
| Avg Trade Size (Sh.) (30 D): |
67 |
| Avg Trade Size (Sh.) (90 D): |
60 |
| Institutional Trades |
| Total Inst.Trades: |
10,068 |
| Avg Inst. Trade: |
$2.98M |
| Avg Inst. Trade (30 D): |
$4.41M |
| Avg Inst. Trade (90 D): |
$4.78M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.86M |
| Avg Closing Trade (30 D): |
$20.06M |
| Avg Closing Trade (90 D): |
$22.19M |
| Avg Closing Volume: |
161.58K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$4.88
|
$1.49
|
$1.36
|
|
Diluted EPS
|
$4.75
|
$1.43
|
$1.33
|
|
Revenue
|
$ 1.24B
|
$ 354.26M
|
$ 325.72M
|
|
Gross Profit
|
$ 1.05B
|
$ 299.02M
|
$ 279.36M
|
|
Net Income / Loss
|
$ 595.49M
|
$ 175.23M
|
$ 165.16M
|
|
Operating Income / Loss
|
$ 737.4M
|
$ 217.92M
|
$ 202.44M
|
|
Cost of Revenue
|
$ 192.06M
|
$ 55.24M
|
$ 46.36M
|
|
Net Cash Flow
|
$ 265.35M
|
$ 357.8M
|
$ -114.47M
|
|
PE Ratio
|
13.33
|
|
|
|
|
|
